Payment overview · 2025
General Payments
$281.71
12 reported records · 7 companies
Healthcare provider profile · identity verified
Jessica G Afable, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · PALM SPRINGS, CA · NPI 1487648929
Verified facts
What the public records show
CMS Open Payments records show Jessica G Afable, M.D received $281.71 in general payments during 2025 across 12 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.08 | 24.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $67.03 | 23.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $38.37 | 13.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.70 | 12.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.00 | 9.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $22.79 | 8.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.74 | 7.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $281.71 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $67.03 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.70 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 761 | 267 |
| Levothyroxine Sodium | Levothyroxine Sodium | 714 | 235 |
| Amlodipine Besylate | Amlodipine Besylate | 592 | 201 |
| Losartan Potassium | Losartan Potassium | 499 | 168 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 472 | 167 |
| Lisinopril | Lisinopril | 391 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 390 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 351 | 150 |
| Gabapentin | Gabapentin | 318 | 111 |
| Metformin Hcl | Metformin Hcl | 308 | 103 |
| Omeprazole | Omeprazole | 283 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 79 |
| Simvastatin | Simvastatin | 234 | 83 |
| Atenolol | Atenolol | 219 | 75 |
| Furosemide | Furosemide | 212 | 69 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 203 | 86 |
| Potassium Chloride | Potassium Chloride | 200 | 62 |
| Trazodone Hcl | Trazodone Hcl | 193 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 190 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 170 | 67 |
| Fluoxetine Hcl | Fluoxetine Hcl | 157 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 55 |
| Meloxicam | Meloxicam | 144 | 56 |
| Celecoxib | Celecoxib | 142 | 63 |
| Eliquis | Apixaban | 128 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 53 |
| Alendronate Sodium | Alendronate Sodium | 118 | 41 |
| Montelukast Sodium | Montelukast Sodium | 116 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 42 |
| Lovastatin | Lovastatin | 110 | 40 |
| Ozempic | Semaglutide | 108 | 35 |
| Donepezil Hcl | Donepezil Hcl | 107 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 35 |
| Ezetimibe | Ezetimibe | 106 | 39 |
| Carvedilol | Carvedilol | 103 | 42 |
| Finasteride | Finasteride | 100 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 38 |
| Memantine Hcl | Memantine Hcl | 94 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 34 |
| Sertraline Hcl | Sertraline Hcl | 93 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 90 | 75 |
| Ibuprofen | Ibuprofen | 90 | 45 |
| Breo Ellipta | Fluticasone/Vilanterol | 87 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 53 |
| Baclofen | Baclofen | 77 | 33 |
| Estradiol | Estradiol | 75 | 29 |
| Allopurinol | Allopurinol | 74 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 55 |
| Benazepril Hcl | Benazepril Hcl | 65 | 20 |
| Synthroid | Levothyroxine Sodium | 65 | 27 |
| Glimepiride | Glimepiride | 62 | 23 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 20 |
| Buspirone Hcl | Buspirone Hcl | 59 | 16 |
| Clonidine Hcl | Clonidine Hcl | 58 | 24 |
| Famotidine | Famotidine | 57 | 27 |
| Tramadol Hcl | Tramadol Hcl | 57 | 39 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 43 |
| Alprazolam | Alprazolam | 55 | 46 |
| Azithromycin | Azithromycin | 55 | 51 |
| Nifedipine Er | Nifedipine | 55 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 19 |
| Valsartan | Valsartan | 53 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 50 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 15 |
| Meclizine Hcl | Meclizine Hcl | 44 | 23 |
| Fenofibrate | Fenofibrate | 43 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 13 |
| Propranolol Hcl | Propranolol Hcl | 43 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 16 |
| Linzess | Linaclotide | 41 | 19 |
| Jardiance | Empagliflozin | 40 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | 18 |
| Methylprednisolone | Methylprednisolone | 39 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 14 |
| Lorazepam | Lorazepam | 38 | 31 |
| Bupropion Xl | Bupropion Hcl | 36 | 12 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Glipizide | Glipizide | 31 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | 11 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 13 |
| Irbesartan | Irbesartan | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | 14 |
| Farxiga | Dapagliflozin Propanediol | 26 | 11 |
| Nitroglycerin | Nitroglycerin | 26 | 20 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 15 |
| Naproxen | Naproxen | 24 | 11 |
| Prednisone | Prednisone | 24 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | 18 |
| Acyclovir | Acyclovir | 23 | 12 |
| Lactulose | Lactulose | 23 | 11 |
| Latanoprost | Latanoprost | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 22 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | 17 |
| Ramipril | Ramipril | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 11 |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Temazepam | Temazepam | 13 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $281.71 · 12 records | Boehringer Ingelheim Pharmaceuticals, Inc. | AREXVY, ELIQUIS, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error